Axinn Obtains Summary Judgment Victory Against FDA
October 22, 2012
A team of attorneys from Axinn successfully obtained summary judgment on behalf of Watson Laboratories, Inc. in litigation against the U.S. Food and Drug Administration in the U.S. District Court for the District of Columbia. The court’s ruling, which is under seal, includes an order that paves the way for the company to bring its generic diabetes drug to market.
The case involved a dispute over the 180-day “first-to-file” marketing exclusivity for generic versions of the multi-billion dollar product Actos® (pioglitazone hydrochloride). FDA had denied exclusivity to Watson in August 2012, instead approving one of Watson’s competitors. In the summary judgment motion, Axinn argued that FDA’s decision should be reversed and that Watson should be entitled to share the marketing exclusivity period.
Today, Judge Amy Berman Jackson issued an order granting Watson Laboratories’ Motion for Summary Judgment, and ordered that the FDA “approve Watson Laboratories' ANDA for generic pioglitazone effective immediately so that Watson may participate in what remains of the shared exclusivity period previously awarded to other generic manufacturers of the drug.”
To subscribe to our publications, click here.
Featured Insights
Featured Insights
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
SCCE 23rd Annual Compliance & Ethics Institute
Speaking Engagement
Antitrust
HNBA/VIA Annual Convention 2025
Sponsorship
Antitrust
Key Appellate Decisions Shaping Antitrust Strategy
Webinar
Antitrust
ACI 12th Annual Summit for Women Leaders in Life Sciences Law
Speaking Engagement
Intellectual Property
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2025
Sponsorship
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Axinn Attorneys Named to the 2025 Lawdragon 500 X – The Next Generation Guide
Awards & Recognitions
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
Hanging in the Balance: Supreme Court Declines to Decide the Uninjured Class Member Question in Labcorp v. Davis
Axinn Viewpoints
Antitrust